These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
464 related articles for article (PubMed ID: 33014070)
1. The Potential Use of Mesenchymal Stem Cells and Their Derived Exosomes as Immunomodulatory Agents for COVID-19 Patients. Alzahrani FA; Saadeldin IM; Ahmad A; Kumar D; Azhar EI; Siddiqui AJ; Kurdi B; Sajini A; Alrefaei AF; Jahan S Stem Cells Int; 2020; 2020():8835986. PubMed ID: 33014070 [TBL] [Abstract][Full Text] [Related]
2. MSC-NTF (NurOwn®) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model. Kaspi H; Semo J; Abramov N; Dekel C; Lindborg S; Kern R; Lebovits C; Aricha R Stem Cell Res Ther; 2021 Jan; 12(1):72. PubMed ID: 33468250 [TBL] [Abstract][Full Text] [Related]
3. Mesenchymal stem cells and their derived exosomes for the treatment of COVID-19. Hou XY; Danzeng LM; Wu YL; Ma QH; Yu Z; Li MY; Li LS World J Stem Cells; 2024 Apr; 16(4):353-374. PubMed ID: 38690515 [TBL] [Abstract][Full Text] [Related]
4. Mesenchymal stem cells and their derived exosomes to combat Covid-19. Yousefi Dehbidi M; Goodarzi N; Azhdari MH; Doroudian M Rev Med Virol; 2022 Mar; 32(2):e2281. PubMed ID: 34363275 [TBL] [Abstract][Full Text] [Related]
5. Hypothesis for the management and treatment of the COVID-19-induced acute respiratory distress syndrome and lung injury using mesenchymal stem cell-derived exosomes. Taghavi-Farahabadi M; Mahmoudi M; Soudi S; Hashemi SM Med Hypotheses; 2020 Nov; 144():109865. PubMed ID: 32562911 [TBL] [Abstract][Full Text] [Related]
6. Potential therapeutic effects and nano-based delivery systems of mesenchymal stem cells and their isolated exosomes to alleviate acute respiratory distress syndrome caused by COVID-19. Ghiasi M; Kheirandish Zarandi P; Dayani A; Salimi A; Shokri E Regen Ther; 2024 Dec; 27():319-328. PubMed ID: 38650667 [TBL] [Abstract][Full Text] [Related]
8. Virology of SARS-CoV-2 and management of nCOVID-19 utilizing immunomodulation properties of human mesenchymal stem cells-a literature review. Sachdeva K; Kumar A; Mohanty S Stem Cell Investig; 2021; 8():23. PubMed ID: 34917676 [TBL] [Abstract][Full Text] [Related]
9. Review of Trials Currently Testing Stem Cells for Treatment of Respiratory Diseases: Facts Known to Date and Possible Applications to COVID-19. Majolo F; da Silva GL; Vieira L; Timmers LFSM; Laufer S; Goettert MI Stem Cell Rev Rep; 2021 Feb; 17(1):44-55. PubMed ID: 32827081 [TBL] [Abstract][Full Text] [Related]
10. Proposed Mechanisms of Targeting COVID-19 by Delivering Mesenchymal Stem Cells and Their Exosomes to Damaged Organs. Jamshidi E; Babajani A; Soltani P; Niknejad H Stem Cell Rev Rep; 2021 Feb; 17(1):176-192. PubMed ID: 33432484 [TBL] [Abstract][Full Text] [Related]
11. Challenges of mesenchymal stem cells in the clinical treatment of COVID-19. Li L; Zhang X; Wu Y; Xing C; Du H Cell Tissue Res; 2024 Jun; 396(3):293-312. PubMed ID: 38512548 [TBL] [Abstract][Full Text] [Related]
12. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial. Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473 [TBL] [Abstract][Full Text] [Related]
13. Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients. Al-Khawaga S; Abdelalim EM Stem Cell Res Ther; 2020 Oct; 11(1):437. PubMed ID: 33059757 [TBL] [Abstract][Full Text] [Related]
15. A potent immunomodulatory role of exosomes derived from mesenchymal stromal cells in preventing cGVHD. Lai P; Chen X; Guo L; Wang Y; Liu X; Liu Y; Zhou T; Huang T; Geng S; Luo C; Huang X; Wu S; Ling W; Du X; He C; Weng J J Hematol Oncol; 2018 Dec; 11(1):135. PubMed ID: 30526632 [TBL] [Abstract][Full Text] [Related]
16. Potential therapeutic application of mesenchymal stem cell-derived exosomes in SARS-CoV-2 pneumonia. Akbari A; Rezaie J Stem Cell Res Ther; 2020 Aug; 11(1):356. PubMed ID: 32795359 [TBL] [Abstract][Full Text] [Related]
17. Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment. Aghayan HR; Salimian F; Abedini A; Fattah Ghazi S; Yunesian M; Alavi-Moghadam S; Makarem J; Majidzadeh-A K; Hatamkhani A; Moghri M; Danesh A; Haddad-Marandi MR; Sanati H; Abbasvandi F; Arjmand B; Azimi P; Ghavamzadeh A; Sarrami-Forooshani R Stem Cell Res Ther; 2022 Jul; 13(1):365. PubMed ID: 35902979 [TBL] [Abstract][Full Text] [Related]
18. Mesenchymal Stem Cell-Based Therapy for COVID-19: Possibility and Potential. Xiong J; Bao L; Qi H; Feng Z; Shi Y Curr Stem Cell Res Ther; 2021; 16(2):105-108. PubMed ID: 32479246 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases. Tsuchiya A; Takeuchi S; Iwasawa T; Kumagai M; Sato T; Motegi S; Ishii Y; Koseki Y; Tomiyoshi K; Natsui K; Takeda N; Yoshida Y; Yamazaki F; Kojima Y; Watanabe Y; Kimura N; Tominaga K; Kamimura H; Takamura M; Terai S Inflamm Regen; 2020; 40():14. PubMed ID: 32582401 [TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stem cells and exosome therapy for COVID-19: current status and future perspective. Gupta A; Kashte S; Gupta M; Rodriguez HC; Gautam SS; Kadam S Hum Cell; 2020 Oct; 33(4):907-918. PubMed ID: 32780299 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]